Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 12/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730277 | 0.97 | NPC1 (0.57) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL18028126 | 0.93 | MAPT (0.49) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL17713154 | 0.90 | CNR1 (0.49) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL18383369 | 0.90 | CNR1 (0.62) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL16730425 | 0.85 | MAPT (0.44) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL16730429 | 0.84 | MAPT (0.49) | NPC1RAB9AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL18028145 | 0.82 | NPC1 (0.45) | NPC1RAB9AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL18028138 | 0.82 | MAPT (0.45) | NPC1RAB9AMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL23000084 | 0.80 | NPC1 (0.77) | NPC1RAB9AMAPK1MAPTCNR1 | |
| SCHEMBL18058762 | 0.78 | HDAC8 (0.41) | NPC1RAB9AMAPK1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417807-B | Preparation method and application of apixaban intermediate | 扬子江药业集团上海海尼药业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | disclosed |
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-05-03 | — | — | US | disclosed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | disclosed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | disclosed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | disclosed |
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (IN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (IN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (IN) | 2017-11-02 | — | — | US | disclosed |
| EP-3212620-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) (IN) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017013079-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2017-01-26 | — | — | WO | disclosed |
| EP-3072892-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| EP-3064497-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2016067308-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LIMITED (FORMERLY JUBILANT LIFE SCIENCES DIVISION) (IN) | 2016-05-06 | — | — | WO | disclosed |
| WO-2015070809-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 成都苑东药业有限公司 | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | NPC1 3778/4885RAB9A 2859/4885MAPK1 1396/4885 |
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F2, FGB, F8 | NPC1 4007/4885RAB9A 1295/4885MAPK1 4254/4885 |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, CYP4X1 | NPC1 2525/4885RAB9A 1434/4885MAPK1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.